Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BRINZOLAMIDE & BRIMONIDINE TARTRATE

All products: Limited Use (codes 393, 466)

Other products in the same Health Canada class (S01E, S01EC) — coverage varies; not interchangeable

  • Acetazolamide (Acetazolamide): general benefit, Not a benefit
  • Methazolamide (Neptazane): general benefit, Not a benefit
  • Brinzolamide (Azopt): limited Use 171, 172, 387
  • Dorzolamide (Trusopt): limited Use 171, 172, 387
  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit

11 more in the class list below

Simbrinza · DIN 02435411 · 1.0% & 0.2% · Oph suspension-10mL Pk

Limited Use — Reason for Use code 466, 393 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 466, 393 required
Write on scriptLU code 466, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 466, 393
Reason for Use code 466 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with brinzolamide or brimonidine. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Simbrinza · DIN 02435411 Manufacturer: Novartis Pharma Canada Inc.; listing date 2015-10-29 Health Canada: Marketed since 2018-04-18 · brand SIMBRINZA · ATC S01EC54 BRINZOLAMIDE, COMBINATIONS, S01EC54 BRINZOLAMIDE, COMBINATIONS · form Suspension · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.2 %/W/V, BRINZOLAMIDE 1 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Simbrinza: Formulary list price $50.6900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $50.6900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91973 · Verify on the e-Formulary ↗ (DIN 02435411)

Source record
DIN 02435411: Simbrinza Raw flags: sec12=Y, sec3=Y Item: 523600143; group id 617; item number 1584; lccId 00258; manufacturer id NOV Source form: Oph Susp-10mL Pk; strength: 1.0% & 0.2% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $50.6900; ministry $50.6900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02435411 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91973
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02435411
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp

DORZOLAMIDE HCL

· 5 products · Limited Use, codes 171, 172, 387 · strengths: 2% · Oph Sol

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk

BRINZOLAMIDE & TIMOLOL MALEATE

· 1 products · Limited Use, codes 310, 393 · strengths: 1% & 0.5% · Oph Susp-5mL Pk

DORZOLAMIDE HCL & TIMOLOL MALEATE

· 11 products · Limited Use, codes 310, 393 · strengths: 2% & 0.5% · Oph Sol, Oph Sol-0.2mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36 and 20 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: intraocular pressure
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. TRAVOPROST · Limited Use, codes 171, 172, 387 INDICATIONS AND CLINICAL USE Sandoz Travoprost is indicated for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension. PM: https://pdf.hres.ca/dpd_pm/00051001.PDF; date May 7, 2019; DIN 02413167; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS SIMBRINZA (brinzolamide / brimonidine tartrate ophthalmic suspension) is indicated for: • the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction AND when the use of SIMBRINZA is considered appropriate. 1.1 Pediatrics Paediatrics (< 18 years of age): The safety and efficacy of SIMBRINZA has not been established in pediatric patients; therefore, Health Canada has not authorized an indication for pediatric use. Several serious adverse reactions have been reported in association with the administration of brimonidine tartrate ophthalmic solution 0.2% in pediatric populations. (see 2 CONTRAINDICATIONS and 7.1.3, Pediatrics). 1.2 Geriatrics Geriatrics (> 65 years of age): No overall differences in safety and effectiveness have been observed between elderly and other adult patients. https://pdf.hres.ca/dpd_pm/00068869.PDF PM date: DEC 23, 2022 Source product: SIMBRINZA; DIN 02435411; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.